Insulin resistance as the core defect in type 2 diabetes mellitus (Q34856847)

4 August 2017

1 reference

title

Insulin resistance as the core defect in type 2 diabetes mellitus (English)

1 reference

4 August 2017

0 references

1 reference

1 reference

Barry J Goldstein

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

American Journal of Cardiology

4 August 2017

published in

1 reference

4 August 2017

1 reference

4 August 2017

1 reference

4 August 2017

page(s)

3G-10G

1 reference

Pathogenesis of NIDDM. A balanced overview

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Pathophysiology of insulin resistance in human disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Insulin resistance and insulin deficiency in the pathogenesis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or of methods?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

The continuing epidemics of obesity and diabetes in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Insulin resistance: current concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Insulin resistance and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Current concepts in the polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Polycystic ovary syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Free fatty acids, insulin resistance, and type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Regional difference in insulin inhibition of non-esterified fatty acid release from human adipocytes: relation to insulin receptor phosphorylation and intracellular signalling through the insulin receptor substrate-1 pathway.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Effect of fatty acids on glucose production and utilization in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Resistin, obesity, and insulin resistance--the emerging role of the adipocyte as an endocrine organ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

The perils of portliness: causes and consequences of visceral adiposity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Mechanisms of TNF-alpha-induced insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Tumor necrosis factor-alpha acutely inhibits insulin signaling in human adipocytes: implication of the p80 tumor necrosis factor receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

The role of TNF alpha in adipocyte metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Weight Reduction Increases Plasma Levels of an Adipose-Derived Anti-Inflammatory Protein, Adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

The hormone resistin links obesity to diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

A family of tissue-specific resistin-like molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Hyperleptinaemia: the missing link in the, metabolic syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Insulin secretion in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Relationships Between Fasting Plasma Glucose Levels and Insulin Secretion During Intravenous Glucose Tolerance Tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Association of fasting glucose levels with a delayed secretion of insulin after oral glucose in subjects with glucose intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Are abnormalities in insulin secretion responsible for reactive hypoglycemia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Arginine-stimulated acute phase of insulin and glucagon secretion in diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Current views on the mechanism of action of thiazolidinedione insulin sensitizers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Unraveling the mechanism of action of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Efficacy of troglitazone on body fat distribution in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Nonhypoglycemic effects of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

Thiazolidinediones, dyslipidaemia and insulin resistance syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2802%2902553-5

10.1016/S0002-9149(02)02553-5

7 January 2021

Identifiers

DOI

1 reference

4 August 2017

1 reference